  |
|||||||
|
|
|
MONDAY 27 MAY 2002 08:00 - 18:00 Registration PLENARY SESSION 5 CELL BIOLOGY: OSTEOBLASTS 08:30 - 09:30 Main Auditorium Chairs: Lance Lanyon (London, UK), 08:30 I-10 The biochemical and cellular characterization of scelerostin, the causative gene for sclerosteosis John Latham (Bothell WA, USA) 09:00 I-11 Role of fos proteins in osteoblast differentiation and function Erwin Wagner (Vienna, Austria) ORAL PRESENTATIONS 4 CELL BIOLOGY: OSTEOBLASTS 09:30 - 10:18 Main Auditorium Chairs: Lance Lanyon (London, UK), 09:30 O-17 THE MULTIPLE FUNCTIONS OF OSTEOBLAST-STIMULATING FACTOR-1 IN BONE DEVELOPMENT H. I. Roach*, R. S. Tare, R. O. C. Oreffo, N. M. P. Clarke University Orthopaedics, University of Southampton, General Hospital, Southampton, UK 09:42 O-18 PROTEIN KINASE D MEDIATES ACTIVATION OF MAP KINASES P38 AND JNK INDUCED BY Gq PROTEIN-COUPLED RECEPTORS IN OSTEOBLAST-LIKE CELLS J. Caverzasio*, J. Lemonnier, Ch. Gayor Dept of Medicine, University Hospital, Geneva, Switzerland 09:54 O-19 FIBROBLAST GROWTH FACTOR-2 INHIBITS APOPTOSIS IN HUMAN CALVARIA OSTEOBLASTS THROUGH A PKC-DEPENDENT PATHWAY F. Debiais, E. Hay, P. J. Marie* INSERM U349 Affiliated CNRS, Paris, France 10:06 O-20 INHIBITION OF OSTEOBLAST APOPTOSIS BY THROMBIN C. N. Pagel, C. Chinni, L. A. Abraham, E. J. Mackie* School of Veterinary Science, University of Melbourne, Parkville, Australia 10:18 - 10:45 Coffee Break WORKSHOP 1 BONE IMAGING 10:45 - 12:15 Main Auditorium Chairs:Mary Bouxsein (Boston MA, USA), 10:45 I-12 Quantitative ultrasound: methods and clinical applications Claus Glüer, (Kiel, Germany) 11:15 I-13 Peripheral or central densitometry: does it matter which technique we use? Ignac Fogelman (London, UK) 11:45 I-14 Advanced imaging of bone WORKSHOP 2 TISSUE ENGINEERING 10:45 - 12:15 Small Auditorium Chairs: Agamemnon Grigoriadis (London, UK), 10:45 I-15 Prospects for cartilage engineering Anthony Hollander (Bristol, UK) 11:15 I-16 Prospects for cell engineeringin bone repair Alan Smith (Baltimore MD, USA) 11:45 I-17 The repair of skeletal defects with BMPs Thomas Einhorn (Boston MA, US) 12.15 ECTS Annual General Meeting Main Auditorium 12:15 - 14:00 Lunch and Poster Session 2 Between 12:15 and 13:15 posters with even numbers will be attended by their presenting author. PLENARY SESSION 6 CANCER AND BONE 14:00 - 15:00 Main Auditorium Chairs: Gregory Mundy (San Antonio TX, USA), 14:00 I-18 Management of cancer-associated bone diseases: new developments Robert Coleman (Sheffield, UK) 14:30 I-19 Osteomalacia tumours, rickets and novel bone-renal molecular pathways Peter Rowe (San Antonio TX, USA) ORAL PRESENTATIONS 5 PATHOGENIC MECHANISMS OF BONE DISEASE 15:00 - 16:12 Main Auditorium Chairs: Gregory Mundy (San Antonio TX, USA), Stuart Ralston (Aberdeen, UK) 15:00 O-21 COEXPRESSION OF BSP AND CBFA1/RUNX2 IN HUMAN MELANOMA: AN INCOMPLETE EPITHELIAL TO OSTEOGENIC CONVERSION AS THE LINK BETWEEN BSP EXPRESSION AND TUMOR INVASIVENESS? M. Riminucci1,2*, A. Corsi1,2, K. Peris3, L. W. Fisher4, S. Chimenti5, S. Licci1, P. Bianco1 1Department of Experimental Medicine and Pathology, La Sapienza University, Rome, Italy; 2Department of Experimental Medicine, Laboratory of Pathology, Univeristy of L'Aquila, Italy; 3Department of Biomedical Sciences, Division of Dermatology, University of L'Aquila, Italy; 4Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA; 5Department of Dermatology, Tor Vergata University, Rome, Italy 15:12 O-22 PROTEIN KINASE C PLAYS AN ESSENTIAL ROLE IN THE REGULATION OF HUMAN CALVARIA OSTEOBLAST PHENOTYPE BY FGF-2, FGFR-2 AND BMP-2 P. J. Marie*, F. Debiais, J. Lemonnier, Ph Delannoy, E. Hay INSERM U349 affiliated CNRS, Paris, France 15:24 O-23 MUTATIONS IN TRANSFORMING GROWTH FACTOR-BETA1 CAUSE CAMURATI-ENGELMANN DISEASE BY AFFECTING EITHER SECRETION OR ACTIVATION OF THE PROTEIN K. Janssens1*, S. H. Ralston2, W. Van Hul1 1Center of Medical Genetics, University of Antwerp, Antwerp, Belgium; 2Department of Medicine and Therapeutics, University of Aberdeen Medical School, Aberdeen, UK 15:36 O-24 MUTATED SUBUNIT A3 OF VACUOLAR PROTON PUMP IN PATIENTS WITH AUTOSOMAL RECESSIVE OSTEOPETROSIS: GENOTYPE-PHENOTYPE CORRELATION A. Taranta1*, A. Ricci1, S. Migliaccio1, I. Recchia1, G. De Rossi2, E. Lanino3, S. H. Ralston4, A. Villa5, P. Vezzoni5, A. Teti1 1Department of Experimental Medicine, University of L'Aquila, Italy; 2Bambino Gesù Hospital, Rome, Italy; 3Gaslini Hospital, Genoa, Italy; 4Dept. of Medicine and Therapeutics, Univ. of Aberdeen, Scotland; 5Istituto di Tecnologìe Biomediche Avanzate, Consiglio Nazionale delle Ricerche, Segrate, Italy 15:48 O-25 ALBERS-SCHÖNBERG DISEASE (AUTOSOMAL DOMINANT OSTEOPETROSIS, TYPE II) IS CAUSED BY MUTATIONS IN THE CLCN7 CHLORIDE CHANNEL GENEE. Cleiren1, O. Bénichou2, E. Van Hul1, J. Gram3, J. Bollerslev4, F. R. Singer5, K. Beaverson6, M. P. Whyte7, M. C. de Vernejoul2, W. Van Hul1*1Dept Medical Genetics, University of Antwerp, Belgium; 2Laboratoire INSERM U 349, Hôpital Lariboisière, Paris, France; 3Dept. Medicine, Ribe County Hospital, Esbjerg, Denmark; 4Dept. Endocrinology, Rikshospitalet, Oslo, Norway; 5John Wayne Cancer Institute, Santa Monica, CA, USA; 6Weill Medical College of Cornell University, New York, NY, USA; 7Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children, St. Louis, MO, USA 16:00 O-26 HARDNESS AND COMPOSITION OF CANCELLOUS BONE IN OSTEOPOROSIS AND OSTEOARTHRITISA. M. Coats1*, P. Zioupos2, R. M. Aspden31Department of Chemistry, University of Aberdeen, Meston Walk, Aberdeen AB24 3UE, UK; 2Materials and Medical Sciences, Cranfield University, Shrivenham SN6 8LA, UK; 3Orthopaedic Surgery, University of Aberdeen, Polworth Building, Foresterhill, Aberdeen AB25 2ZD, UK 16:12 - 16:30 Coffee Break SYMPOSIUM CANCER ASSOCIATED BONE DISEASE AND THE MEDICAL MANAGEMENT OF
HYPERCALCAEMIA Generously supported by Roche 16:30 - 18:00 Small Auditorium 16:30 Pathophysiology of cancer associated bone disease Gregory Mundy (San Antonio TX, USA) 17:00 Clinical spectrum and morbidity of bone disease in cancer Robert Coleman (Sheffield, UK) 17:30 Hypercalcaemia: pathogenesis and management (plus presentation of guidelines) Stuart Ralston (Aberdeen, UK) |
|||||
 |
|||||||
